GPHN and schizophrenia: In light of the fact that rare exonic deletions implicate gephyrin in risk for autism, schizophrenia and seizures (e.g., Lionel et al., 2013), these findings make rTMS an interesting clinical tool for the modulation of gephyrin-mediated inhibitory synaptic plasticity.